GSK and Save the Children are committed to working together to help save the lives of one million children. As part of the global partnership between GSK and Save the Children, we are pleased to announce the launch of the third annual Healthcare Innovation Award which will provide USD$ 1 million to reward organisations practicing innovative approaches for improving and increasing healthcare for children under the age of five. The organisations judged to strengthen health systems in the most innovative and effective ways will be eligible for an Award of up to USD$ 400,000.
Eligible innovative organisations can come from the non-profit, private or public sector, if both the organisation and the innovation are from the developing world. Nominations can be submitted by the organisation themselves, or an organisation may be nominated by a third-party organisation or individual, through a brief questionnaire found within the detailed guidelines.
GSK and Save the Children are working in partnership to fight child mortality and improve newborn survival in developing countries. An Award fund of USD$ 1 million has been made available by GSK for organisations practicing innovative approaches to increase access to and the quality of healthcare for newborns and children under-5. Innovation is a match between a new solution and an unmet need that involves the creation and implementation of new processes, products, systems, services and/or methods of delivery.
This is an electronic Request-for-Partners (eRFP) Challenge, but you do not need to represent the innovative organisation in order to make a nomination. Nominations must be submitted using the provided template. GSK and Save the Children will jointly evaluate nominated organisations and select organisations for a monetary Award. During this evaluation, GSK and/or Save the Children may contact selected organisations directly to carry out required due diligence and to make further arrangements as necessary. The monetary value of Awards made will be based on the Judging Panel’s assessment of submissions against Award criteria and will vary between submissions.
Submissions to this Challenge must be received by 11:59 PM (23:59) GMT on September 7, 2015.
Late submissions will not be considered.
Award winners selected by GSK and Save the Children will be publically announced and their innovative practices promoted within 6 months of the end of the nomination period.
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.